Section Arrow
Quote
ADPT.NASDAQ
- Adaptive Biotechnologies Corp
Quotes are at least 15-min delayed:2026/04/09 15:17 EDT
Regular Hours
Last
 13.665
-1.175 (-7.92%)
Day High 
14.735 
Prev. Close
14.84 
1-M High
15.6125 
Volume 
1.13M 
Bid
13.66
Ask
13.67
Day Low
13.62 
Open
14.7 
1-M Low
12 
Market Cap 
2.28B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.91 
20-SMA 13.68 
50-SMA 15.31 
52-W High 20.76 
52-W Low 6.7747 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.39/-1.19
Enterprise Value
2.35B
Balance Sheet
Book Value Per Share
1.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
276.98M
Operating Revenue Per Share
1.23
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ONCOOnconetix Inc.1.305+0.175+15.49%0PE
GLMDGalmed Pharmaceuticals Ltd0.8641+0.24165+38.82%-- 
QNCXQuince Therapeutics0.1236-0.0595-32.50%-- 
ELABPmgc Holdings Inc5.59+1.09+24.22%0PE
IOVAIovance Biotherapeutics3.92+0.45+12.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.